Cancer Treatment Reviews
Volume 30, Issue 8 , Pages 711-713, December 2004

Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer:☆☆☆☆☆☆

Abstracted from: André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51

published online 26 October 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Sanofi-Synthelabo, the manufacturer of oxaliplatin.

☆☆ For Correspondence Dr. de Gramont, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France. E-mail: aimery.de-gramont@sat.ap-hop-paris.fr.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(04)00148-3

doi:10.1016/j.ctrv.2004.09.002

Cancer Treatment Reviews
Volume 30, Issue 8 , Pages 711-713, December 2004

Article Tools